Physician profile
James Yi Lin
NPI 1164599155
$72,962.94
in general payments reported to CMS, 2019-2025
56 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $246 · 2021: $685 · 2022: $2,217 · 2023: $23K · 2024: $28K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,250 · Food and Beverage: $7,577 · Consulting Fee: $5,750 · Travel and Lodging: $3,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,851.92 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,250.00 |
| Food and Beverage | $7,576.62 |
| Consulting Fee | $5,750.00 |
| Travel and Lodging | $3,764.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reapplix INC. | $32,326.13 | 2023-2025 | 3c Patch Kit - Box |
| Organogenesis INC. | $29,479.76 | 2021-2025 | Puraply Wound Matrix, Affinity, Puraply Antimicrobial |
| Merz North America, INC. | $4,150.11 | 2023-2025 | Xeomin |
| Boston Scientific Corporation | $1,085.92 | 2023 | Varithena Administration Pack |
| Medtronic, INC. | $749.79 | 2022-2025 | Venaseal, Intellis Adaptivestim |
| Galderma Laboratories, L.P. | $690.97 | 2020-2025 | |
| Smith+Nephew, INC. | $569.85 | 2022-2025 | Grafix Pl, Renasys Touch, Allevyn Heel 10.5cm X 13.5cm Ctn 5 |
| Novo Nordisk INC | $345.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $321.77 | 2019-2025 | Amyvid, Kisunla, Mounjaro |
| Pfizer INC. | $253.35 | 2019-2025 | |
| Eisai INC. | $239.87 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $231.23 | 2019-2025 | Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $203.15 | 2019-2025 | |
| Baxter Healthcare | $196.07 | 2024 | Hillrom - Centrella Smart+ Bed |
| Janssen Pharmaceuticals, INC | $181.12 | 2019-2024 | Xarelto |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.